Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Homology Medicines Stock Performance
Shares of Homology Medicines stock opened at $2.76 on Friday. The stock has a market cap of $158.40 million, a P/E ratio of -34.50 and a beta of -0.36. The stock's fifty day moving average is $2.22 and its 200 day moving average is $2.49. Homology Medicines has a one year low of $1.30 and a one year high of $8.90.
Homology Medicines (NASDAQ:FIXX - Get Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. Homology Medicines had a negative return on equity of 49.48% and a negative net margin of 47.29%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $1.30 million. Analysts predict that Homology Medicines will post -1.86 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on FIXX. Chardan Capital decreased their price objective on shares of Homology Medicines to $14.00 and set a "na" rating for the company in a report on Tuesday, May 17th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Homology Medicines in a report on Monday, May 23rd. Finally, Credit Suisse Group set a $3.10 target price on shares of Homology Medicines in a research note on Monday, June 20th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $13.01.